Noble and Aptar Pharma are pleased to announce the launch of AdhereIT™ - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms. This launch is an important advancement for Noble, an Aptar Pharma company, whose mission is to foster healthy outcomes for patients who self-administer their therapies, partnering with pharma and biotech companies to provide robust training devices and onboarding programs.
Adherence to prescribed biologics is a significant challenge. A recent report in the Journal of the American Academy of Dermatology reported that 45% of studied patients suffering from psoriasis discontinue their treatments. The reasons include insufficient training or time with an instructor, lack of confidence during the self-injection process, and feelings of high anxiety and lack of control. COVID-19 has contributed to the increased utilization of telemedicine and remote healthcare, which has even further complicated this challenge by reducing healthcare professional (HCP) training opportunities with patients.
AdhereIT is part of the digital ecosystem that enables patients to gain control and confidence over their at-home drug delivery while easing the anxiety associated with self-injecting. AdhereIT integrates with the existing software applications developed by the Digital Healthcare team at Aptar Pharma by pairing a patient’s autoinjector via Bluetooth technology to their mobile phone. The device – available in two design options to accommodate dexterity for a one-handed or two-handed injection process – precisely detects an injection event and provides real-time visual, audio and haptic feedback about whether the injection was performed correctly. The AdhereIT on boarding platform also allows HCPs to monitor their patients’ therapeutic performance via a smart analytical dashboard, providing valuable patient-specific adherence behavior information.
“We are excited to welcome Noble’s AdhereIT connected onoarding platform into the suite of Aptar Pharma’s Digital Healthcare solutions. This innovative technology further enhances our ability to improve patients’ lives by creating a seamless integration of injectable products into our disease management offerings,” said Adam Shain, Director of Business Development for Digital Healthcare, Aptar Pharma.
Noble developed AdhereIT in partnership with Aptar Pharma, who has made significant investments in digital healthcare over the past three years to actively develop a portfolio of disease management platforms and connected device solutions across dermal, pulmonary, nasal, ophthalmic and injectable routes of administration.
“Connected medical devices represent the future of healthcare for patients, pharmaceutical companies, health insurers and HCPs, playing a vital role in the remote tracking and treatment of chronic illnesses, and delivering a range of benefits that include improved drug management, enriched patient experiences and enhanced patient outcomes,” said Tim McLeroy, Noble’s Executive Director of Marketing & Patient Services. “The connectivity of digital technology solutions like AdhereIT also create market differentiation and enable value-based contracting for biopharmaceutical companies and medical device manufacturers to survive in a competitive and challenging marketplace.”
Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield
AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.
Aptar Pharma has partnered with Luin to launch India’s first connected device for metered-dose inhalers (MDI) called ADHERO. This unique add-on smart device is designed to help patients with chronic respiratory diseases track their MDI usage and facilitate improved adherence to their prescribed therapy.
Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.
Aptar Pharma to host three insightful Learning Lab sessions
Aptar Pharma will host three insightful Learning Lab sessions on Wednesday, February 5 at Pharmapack. The sessions are entitled Rethinking DPI Packaging: New Solutions to Old Challenges; Accelerating and derisking your drug development journey; and Inhaler Devices and the Environment: Going Green Needn’t Cost the Earth.
Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation
Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products.
Aptar Pharma highlights expanded services platform
Aptar Pharma is highlighting its diverse portfolio of drug delivery systems, components and active packaging solutions, including their latest innovations addressing nasal, pulmonary, eye care, injectables and dermal drug delivery routes, including PureHale, a dedicated Connectivity hub hosting Aptar Pharma’s expanding range of connected drug delivery devices and Nanopharm’s SmartTrack.
Aptar Pharma, a leading provider of drug delivery devices worldwide and part of AptarGroup, Inc. has announced that its patented Unidose Liquid System is the device which delivers Tosymra Nasal Spray 10mg, for the acute treatment of migraine in adults. Aptar’s Unidose device delivers one dose of Tosymra as a single spray providing a convenient, patient-friendly delivery approach.
Aptar’s Nasal Unidose Device approved by US FDA
AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.
AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.
Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award
Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.
Aptar Pharma co-organizer and diamond sponsor of RDD Europe 2019 conference in Estoril, Portugal
Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its co- organization and diamond sponsorship of the Respiratory Drug Delivery Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.
Aptar Pharma, a leading drug delivery systems provider, has announced that its Bidose nasal spray device was recently approved by the US FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and US launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.
Aptar Pharma's preservative-free multidose dispenser approved across Europe for Santen's Taflotan/Saflutan prescription treatment
Aptar Pharma is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been approved for Santen’s prescription drug Taflotan/Saflutan for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension in 26 countries in Europe.
Aptar Pharma QuickStart Injectables wins Industry Innovation Award at Pharmapack 2019
Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that their recently-launched QuickStart for Injectables has won Best Innovation in Packaging Material & Component category at the 2019 Pharmapack Awards in Paris, France.
Aptar Pharma is bringing the respiratory world together
Aptar Pharma is pleased to announce the co-organization and diamond sponsorship of the Respiratory Drug Delivery Europe 2019 scientific conference, which will connect pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal, May 7-10, 2019.
Aptar Pharma showcases PureHale and QuickStartTM Injectables product launches
As part of the Innovation Gallery at Pharmapack this year, Aptar Pharma will showcase two of their newest product launches, PureHale and QuickStartTM Injectables – their Ready-to- Use drug development support packages designed to accelerate time-to-market for research and development labs. Both innovations are contenders for the Pharmapack 2019 Awards, which will be announced during the show.
Aptar Pharma co-organizes the third edition of RDD Asia
Aptar Pharma is pleased to announce the co-organization and its diamond sponsorship of the third Respiratory Drug Delivery (RDD®) Asia scientific conference, which will welcome internationally renowned speakers in pulmonary and nasal drug delivery. The conference will be held at the Grand Hyatt Kochi hotel from November 14th-16th in Kerala, India.
Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.
Aptar Pharma QuickStart, an injectable device development kit, to launch at CPhI Worldwide
Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, October 9th.
Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"
Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..
Aptar Pharma to host live webinar on decoding the FDA's recent combination drug product guidance
Aptar Pharma, a leading drug delivery systems provider, will host a live webinar on September 18, 2018 to provide insight into how the FDA’s 2018 guidance affects future Combination Product submissions for respiratory and nasal drug products, specifically DPIs, pMDIs, and Nasal Sprays.
Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the approved delivery device for Bausch+Lomb’s Levofree Multidose in France. This marks the first approval by the French National Agency for Medicines and Health Products Safety (ANSM) for Aptar Pharma’s Ophthalmic Squeeze Dispenser.
Aptar Pharma to Host Connected Health Webinar “Digital Healthcare: Are You Ready to Connect?” on February 22
Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar on the benefits of connected drug delivery devices, with a particular focus on improving patient regimen compliance and outlining the benefits to the whole healthcare ecosystem.
Aptar Pharma, a leading provider of innovative drug delivery systems, has announced it will be hosting a live, complimentary webinar titled “Optimizing Patient Adherence and Compliance in Eye Care” on November 21 at 11AM EST. The webinar will offer expert insight from Matthias Birkhoff, Vice President Business Development at Aptar Pharma, and Dr. Degenhard Marx, Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division.
Aptar Pharma's electronic lockout device approved by EMA
Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.
Pulmonary and Nasal Drug Delivery Experts to attend RDD Europe 2017
The Respiratory Drug Delivery (RDD®) Europe 2017 scientific conference will welcome pulmonary and nasal drug delivery experts from around the world to Antibes, France, April 25-28, 2017. The joint organizers of this event, RDD Online® and Aptar Pharma invite you to register.
Pulmonary and nasal drug delivery experts to attend RDD Europe 2017
Register now to attend the RDD Europe 2017 Scientific Conference to be held April 25-28, 2017, in Antibes, France. The Respiratory Drug Delivery (RDD) Europe 2017 scientific conference will welcome pulmonary and nasal drug delivery experts from around the world to Antibes, France, April 25-28, 2017.
- Jo Webb
- Product Info
- Created 05 Oct 2020
- Modified 08 Oct 2020
- Hits 167